New to The Street TV welcomes David Luci, the President / CEO at Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). From the Nasdaq Marketplace studio, David talks with TV Host Jane King about the Company’s clinical biopharmaceutical business developing a new class of antibiotics for bacterial infections. David discusses the Company’s novel Ibezapolstat drug, a potential treatment for Clostridioides difficile Infections (CDI). With the recent positive outcome from Ibezapolstat’s FDA Phase 2a clinical and microbiome data, the Company is now enrolling patients for its FDA Phase 2b trial. CDI kills about 29,000 people annually; many catch the infection in hospitals and nursing homes. Clinical data to date shows that Ibezapolstat increases the good microbiome bacteria in the gut, and it demonstrated eradication of CDI during 3-days of treatment. David references Summit Therapeutics, and their recent Phase 3 FDA failure on a competitive CDI drug. There has been NO new class of antibiotic drugs since 1984, and the current frontline treatment Vancomycin, has limitations with about a 15-20% rate of CDI recurrence. Big Pharma wants a new class of antibiotics to combat CDI and other bacterial infections. David explains that being public is essential and helps the Company raise money, as needed, going forward with current and other pipeline treatments. Private and Governmental organization grants are a good source for early-stage development of new novel drug products. David will do a follow-up interview to inform viewers of the progress with the Ibezapolstat drug and the Company. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. – https://www.acurxpharma.com/
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list
